Halozyme Therapeutics, Inc. (HALO) Live Share Price, Invest From India

Halozyme Therapeutics, Inc. Stock Performance

as on January 21, 2026 at 8:38 pm IST

Day's Low
Day's High
$69.73
Day's Price Range
$70.73
$70.81
1.53%
Downside
-0.11%
Upside
52 Week's Low
52 Week's High
$47.50
52-Week Price Range
$79.50
$70.81
32.92%
Downside
12.27%
Upside

Halozyme Therapeutics, Inc. share price movements today

Previous Close: $70.43
Open: $70.31
Volume: 78.8K
Day's Low - High: $69.73 - $70.73
52 Week Low - High: $47.50 - $79.50

Halozyme Therapeutics, Inc. Historical Returns

1 Month Return: + 4.57 %
3 Month Return: + 5.31 %
1 Year Return: + 25.9 %
3 Year Return: + 36.86 %
5 Year Return: + 48.27 %

Halozyme Therapeutics, Inc. Stock Fundamentals & Key Indicators

Check Halozyme Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$8.4B

EPS (TTM)

6.254

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.36%

PE Ratio (TTM)

15.02

Industry PE ratio

6.809270833333334

PEG Ratio

-2.5

EBITDA

813.3M

Revenue (TTM)

1.2B

Profit Margin

47.91%

Return On Equity TTM

124.50%

Halozyme Therapeutics, Inc. Stock Valuation

Track how Halozyme Therapeutics, Inc. P/E has moved over time to understand its valuation trends.

Halozyme Therapeutics, Inc. in the last 5 years

Overview
Trends

Lowest (10.98x)

June 30, 2025

Industry (6.81x)

January 21, 2026

Today (15.02x)

January 21, 2026

Highest (34.85x)

March 31, 2021

LowHigh

Today’s Price to Earnings Ratio: 15.02x

Halozyme Therapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Halozyme Therapeutics, Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Halozyme Therapeutics, Inc.	BUY	$8.4B	48.27%	15.02	47.91%
Alnylam Pharmaceuticals, Inc.	BUY	$47.4B	113.21%	1237.91	1.36%
Vertex Pharmaceuticals Incorporated	BUY	$113.2B	85.25%	31.06	31.35%
Beone Medicines Ltd	NA	$37.4B	NA	663.12	1.38%
Regeneron Pharmaceuticals, Inc.	BUY	$77.7B	37.03%	17.57	32.13%

Stock Returns calculator for Halozyme Therapeutics, Inc. Stock including INR - Dollar returns

The Halozyme Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Halozyme Therapeutics, Inc. investment value today

Current value as on today

₹1,32,615

Returns

₹32,615

(+32.62%)

Returns from Halozyme Therapeutics, Inc. Stock

₹26,582 (+26.58%)

Dollar Returns*

₹6,033 (+6.03%)

Analyst Recommendation on Halozyme Therapeutics, Inc. Stock

Based on 17 analysts

BUY

82.35%

Buy

17.65%

Hold

0.00%

Sell

Based on 17 analysts, 82.35% of analysts recommend a 'BUY' rating for Halozyme Therapeutics, Inc.. Average target price of $77.12

Halozyme Therapeutics, Inc. Share Price Target

Get share price movements and forecasts by analysts on Halozyme Therapeutics, Inc..

What analysts predicted

8.18%UPSIDE

Target Price

$77.12

Current Price

$70.81

Analyzed by

17 Analysts

Target

$77.12

Halozyme Therapeutics, Inc. target price $77.12, a slight upside of 8.18% compared to current price of $70.81. According to 17 analysts rating.

Halozyme Therapeutics, Inc. Stock’s Investor Sentiment and Interest

Search interest for Halozyme Therapeutics, Inc. Stock has decreased by -35% in the last 30 days, reflecting a downward trend in search activity.

Time period: December 22, 2025 to January 21, 2026

Change:-35% versus previous 30 day period

Halozyme Therapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Total Revenue	221	216	230	195	231	290	298	264	325	354
Gross Profit	170	161	177	149	173	240	255	216	279	299
Operating Income	94	88	101	95	117	163	175	141	202	217
EBITDA	118	129	127	115	137	190	203	168	229	284
Interest Expense	4	4	5	4	4	4	4	4	4	4
Depreciation	20	20	20	20	20	20	20	20	20	20
Income Before Tax	93	101	101	96	117	165	178	143	204	218
Income Tax Expense	18	19	15	19	24	28	41	25	39	43
Net Income	74	81	85	76	93	137	137	118	165	175
Net Profit Margin	33.82%	37.88%	37.12%	39.22%	40.30%	47.23%	45.98%	44.59%	50.71%	49.46%

Halozyme Therapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	135	146	316	151	195	267	443	660	829	1,015
Gross Profit	105	113	285	141	150	224	361	520	636	855
Operating Income	-27	-83	81	-69	-67	144	275	267	337	551
EBITDA	-25	-80	83	-66	-63	147	278	315	451	656
Interest Expense	5	19	21	18	11	20	7	16	18	18
Depreciation	-	-	2	2	4	3	2	49	84	81
Income Before Tax	-32	-101	61	-79	-72	129	248	248	348	557
Income Tax Expense	3	1	-1	0	0	0	-154	46	66	113
Net Income	-32	-103	62	-80	-72	129	402	202	281	444
Net Profit Margin	-23.86%	-70.23%	19.89%	-52.90%	-36.86%	48.24%	90.84%	30.62%	33.96%	43.74%

Halozyme Therapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Net Income	81	85	76	93	137	137	118	165	175
Operating Cash Flow	132	102	129	55	115	178	154	99	178
Investing Cash Flow	-83	-8	-82	-42	-167	29	-90	84	201
Financing Cash Flow	4	-249	0	9	18	-246	-3	-298	-22
Change in Cash	53	-155	46	23	-33	-38	60	-114	357

Halozyme Therapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	-103	62	-80	-72	129	402	202	281	444
Operating Cash Flow	-50	134	-49	-85	55	299	240	388	479
Investing Cash Flow	-76	-163	2	-5	78	-406	-487	-96	-262
Financing Cash Flow	150	131	-63	153	-106	77	362	-407	-218
Change in Cash	23	101	-110	62	27	-28	115	-116	-2

Global Institutional Holdings in Halozyme Therapeutics, Inc.

Funds	Holdings
Geode Capital Management, LLC	2.08%
Bank of America Corp	1.77%
Goldman Sachs Group Inc	1.17%
Charles Schwab Investment Management Inc	1.15%
Morgan Stanley - Brokerage Accounts	1.51%

See all

Halozyme Therapeutics, Inc. News & Key Events

Insights on Halozyme Therapeutics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Best in 3 Years
In the last 3 years, HALO has outperformed top 5 stocks with highest market-cap in its industry
POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 3 quarters, 118.09M → 175.22M (in $), with an average increase of 17.1% per quarter
POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 264.86M → 354.26M (in $), with an average increase of 13.4% per quarter
NO EFFECT
Against Peers
In the last 1 year, Beone Medicines Ltd has given 52.8% return, outperforming this stock by 26.9%
NEGATIVE IMPACT
Price Dip
In the last 7 days, HALO stock has moved down by -3.5%

About Halozyme Therapeutics, Inc.

we are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. our lead proprietary program, investigational drug pegph20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. by breaking down potential barriers to cancer, pegph20 may help make existing treatments more effective by allowing therapies to reach the tumor. we are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, roche, pfizer, janssen, baxalta, abbvie and lilly, for our enhanze™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. this technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. we are a diverse team, who are committed to bringing therapies

Organisation	Halozyme Therapeutics, Inc.
Headquarters	12390 El Camino Real, San Diego, CA, United States, 92130
Industry	Health Technology
CEO	Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
E-voting on shares	Click here to vote

Key Management of Halozyme Therapeutics, Inc.

Name	Title
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.	President, CEO & Director
Ms. Nicole LaBrosse CPA	Senior VP & CFO
Mr. Mark Snyder Esq.	Senior VP, General Counsel, Chief Compliance Officer & nd Secretary
Ms. Cortney Caudill M.B.A.	Senior VP & COO
Ms. Tram Bui	Head of Investor Relations & Corporate Communications
Dr. Christopher Wahl M.B.A., M.D.	Chief Scientific Officer
Mr. Rhys de Callier	Chief Strategy Officer
Dr. Charles P. Theuer M.D., Ph.D.	Chief Medical Officer
Mr. Paul Spence	Chief Commercial Officer
Mr. Chase Coffman Ph.D.	President of Hypercon

FAQs

What is Halozyme Therapeutics, Inc. share price today?

Halozyme Therapeutics, Inc. share price today is $70.81 as on January 21, 2026 at 8:38 pm IST. Halozyme Therapeutics, Inc. share today touched a day high of $70.73 and a low of $69.73.

What is the 52 week high and 52 week low for Halozyme Therapeutics, Inc. share?

Halozyme Therapeutics, Inc. share touched a 52 week high of $79.5 on September 23, 2025 and a 52 week low of $47.5 on May 14, 2025. Halozyme Therapeutics, Inc. stock price today i.e. January 21, 2026 at 8:38 pm IST is trending at $70.81,which is 10.93% down from its 52 week high and 49.07% up from its 52 week low.

What is Halozyme Therapeutics, Inc.'s market capitalisation today?

Halozyme Therapeutics, Inc. market capitalisation is $0.01T as on January 21, 2026 at 8:38 pm IST.

How to invest in Halozyme Therapeutics, Inc. Stock (HALO) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Halozyme Therapeutics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Halozyme Therapeutics, Inc. Shares that will get you 0.0212 shares as per Halozyme Therapeutics, Inc. share price of $70.81 per share as on January 21, 2026 at 8:38 pm IST.

What is the minimum amount required to buy Halozyme Therapeutics, Inc. Stock (HALO) from India?

Indian investors can start investing in Halozyme Therapeutics, Inc. (HALO) shares with as little as ₹91.673 or $1 (as of January 21, 2026 at 8:38 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹916.73 in Halozyme Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on January 21, 2026 at 8:38 pm IST). Based on Halozyme Therapeutics, Inc. share’s latest price of $70.81 as on January 21, 2026 at 8:38 pm IST, you will get 0.1412 shares of Halozyme Therapeutics, Inc.. Learn more about fractional shares .

What are the returns that Halozyme Therapeutics, Inc. has given to Indian investors in the last 5 years?

Halozyme Therapeutics, Inc. stock has given 48.27% share price returns and 24.57% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?